DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Ubicación actual:
> This Story

Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment



Oncology Homepage

New PET imaging method may yield benefits over FDG for detecting certain cancers Gallium-68-labeled FAPI tracer yields promising results

Israeli startup Alpha Tau Medical raises $29 million for novel radiotherapy New brachytherapy approach could be useful for treating several cancers

Dr. Carri Glide-Hurst American Association of Physicists in Medicine elects fellow

Cecilia Danckwardt-Lillieström C-RAD appoints new CFO

Fox Chase Cancer Center gets $673K grant to develop early-stage lung cancer test Taking aim at false positive CT lung scans

Radiotherapy may cause gaps in memory recall for children, says study Trouble recalling specifics of events after treatment

New brachytherapy approach deemed safe for clinical trials First alpha radiation-based cancer treatment for solid tumors

Radiotherapy vacancies rise above three percent, says ASRT survey Vacancies highest in Pacific region of U.S.

AI model strikes balance between dose toxicity and tumor reduction Minimizes dose while still shrinking tumor

Guerbet teams with Imalogix to enhance dose management Utilizes Imalogix's AI-based process and workflow solutions

The Court of Appeal of Nantes
rejected Varian's attempt to have the
University Hospital of Tours' purchase of
Accuray's TomoTherapy System cancelled

Court rejects Varian’s final appeal over French hospital’s purchase of Accuray device

por John R. Fischer , Staff Reporter
A European court has rejected an appeal filed by Varian Medical Systems against a French hospital over its choice of medical devices for the treatment of cancer patients.

The Court of Appeal of Nantes in France ruled against Varian’s attempt to have the University Hospital of Tours' (CHU) purchase of Accuray Incorporated’s TomoTherapy System cancelled. The decision marks the final verdict in a case involving a series of motions and appeals filed by Varian against the facility.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

“Throughout the various lawsuits, Varian claimed that they had been unduly restricted from the tendering procedure because, according to Varian, their devices could offer a technology similar to the Accuray TomoTherapy System,” Birgit Fleurent, chief marketing officer at Accuray, told HCB News. “The Court has confirmed all previous rulings and rejected Varian's claims.”

The court of appeal ruled that the tender award in favor of TomoTherapy Europe was valid and that the administrative documents regarding the tender defined the medical needs of CHU Tours sufficiently.

It also declared the TomoTherapy system to be the only radiation therapy device that administers a continuous helical delivery of radiation from 360 degrees around the patient, a method for delivering image-guided IMRT which enables optimal modulation of dose and the irradiation of large fields without the need to reposition patients.

Such a technique, it said, is recommended by the French National Authority for Health (HAS) in treatment for craniospinal irradiations, in cases involving pediatric tumors and for total body irradiation in the treatment of blood tumors; and that Varian failed to prove its technology could meet the clinical needs of CHU.

“The ruling is important because it emphasizes a clinical team's right to select the radiation therapy system they feel best meets the needs of their facility, team and patients,” said Fleurent. “It highlights the importance of the clinical team's voice in the purchasing decision. With regard to this specific verdict it reinforces the unique, differentiated benefits provided by the TomoTherapy platform, including both TomoTherapy and Radixact Systems.”

Varian first filed a claim in May 2014 to request the cancellation of the tender award for the TomoTherapy System in a motion that was dismissed soon after. The company appealed the decision to a higher court, which rejected it. Another suit was then filed in the administrative court and followed by an appeal to the Court of Appeal of Nantes.

Varian expressed disappointment over the verdict. "We respectfully disagree with the court's decision,” Varian told HCB News. “We are focused on our business moving forward and will have no further comment on this case."

CHU Tours is the first hospital in France to adopt the TomoTherapy System and CyberKnife System. It did not respond for comment.

Oncology Homepage

You Must Be Logged In To Post A Comment

Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2018, Inc.